# Yutaka Fujiwara

## List of Publications by Year in descending order



| | | | |
|---|---|---|---|
| 119 papers | 3,077 citations | 147566 31 h-index | 197535 49 g-index |
| 119 all docs | 119 docs citations | 119 times ranked | 5463 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | A Novel Serum Metabolomics-Based Diagnostic Approach to Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 571-579. | 1.1 | 157 |
| 2 | High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Science, 2006, 97, 642-648. | 1.7 | 138 |
| 3 | Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 2528-2537. | 3.2 | 137 |
| 4 | Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Science, 2018, 109, 3583-3590. | 1.7 | 118 |
| 5 | Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, 385-390. | 1.1 | 115 |
| 6 | Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Investigational New Drugs, 2012, 30, 1352-1360. | 1.2 | 100 |
| 7 | PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer, 2017, 108, 115-120. | 0.9 | 98 |
| 8 | Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer, 2016, 99, 4-10. | 0.9 | 81 |
| 9 | Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2015, 76, 1143-1152. | 1.1 | 73 |
| 10 | Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors. Japanese Journal of Clinical Oncology, 2009, 39, 260-266. | 0.6 | 57 |
| 11 | Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Investigational New Drugs, 2012, 30, 1055-1064. | 1.2 | 56 |
| 12 | Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Lung Cancer, 2018, 124, 179-188. | 0.9 | 56 |
| 13 | Epidermal Growth Factor Receptor Mutation IsÂAssociated With Longer Local Control After Definitive Chemoradiotherapy in Patients WithÂStage III Nonsquamous Nonâ€“Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 140-148. | 0.4 | 53 |
| 14 | Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 281-288. | 1.1 | 51 |
| 15 | Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to AssessEGFRMutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors. Oncologist, 2016, 21, 156-164. | 1.9 | 50 |
| 16 | Phase II study of nabâ€paclitaxelÂ+Âcarboplatin for patients with nonâ€smallâ€cell lung cancer and interstitial lung disease. Cancer Science, 2019, 110, 3738-3745. | 1.7 | 49 |
| 17 | First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics, 2019, 18, 531-540. | 1.9 | 49 |
| 18 | Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTINâ„¢), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2009, 64, 1165-1172. | 1.1 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Investigational New Drugs, 2015, 33, 881-889. | 1.2 | 46 |
| 20 | The genomic and epigenomic landscape in thymic carcinoma. Carcinogenesis, 2017, 38, 1084-1091. | 1.3 | 46 |
| 21 | Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Investigational New Drugs, 2016, 34, 596-603. | 1.2 | 43 |
| 22 | An overview of the recent progress in irinotecan pharmacogenetics. Pharmacogenomics, 2010, 11, 391-406. | 0.6 | 41 |
| 23 | Metabolomics Evaluation of Serum Markers for Cachexia and Their Intra-Day Variation in Patients with Advanced Pancreatic Cancer. PLoS ONE, 2014, 9, e113259. | 1.1 | 40 |
| 24 | Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Science, 2009, 100, 1728-1734. | 1.7 | 39 |
| 25 | Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel. Journal of Thoracic Oncology, 2009, 4, 208-213. | 0.5 | 38 |
| 26 | Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma. BMC Research Notes, 2015, 8, 800. | 0.6 | 38 |
| 27 | Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors. Investigational New Drugs, 2012, 30, 1950-1957. | 1.2 | 37 |
| 28 | A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 74, 15-23. | 1.1 | 37 |
| 29 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. Auris Nasus Larynx, 2016, 43, 677-684. | 0.5 | 37 |
| 30 | First-in-Human Phase 1 Study of MORAb-202, an Antibodyâ€“Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-Î±â€“Positive Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 3905-3915. | 3.2 | 37 |
| 31 | Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma. Future Oncology, 2019, 15, 1911-1920. | 1.1 | 36 |
| 32 | Effect of Platinum Combined with Irinotecan or Paclitaxel against Large Cell Neuroendocrine Carcinoma of the Lung. Japanese Journal of Clinical Oncology, 2007, 37, 482-486. | 0.6 | 34 |
| 33 | Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. Cancer Science, 2021, 112, 2361-2370. | 1.7 | 33 |
| 34 | Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. Oncotarget, 2018, 9, 23729-23737. | 0.8 | 33 |
| 35 | Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer, 2015, 89, 287-293. | 0.9 | 29 |
| 36 | Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study. Cancer Chemotherapy and Pharmacology, 2014, 74, 699-709. | 1.1 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | PhaseÂI clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothiloneÂB analog, in Japanese patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2008, 61, 751-758. | 1.1 | 26 |
| 38 | Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. International Journal of Oncology, 2012, 41, 551-558. | 1.4 | 26 |
| 39 | Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer. Investigational New Drugs, 2017, 35, 37-46. | 1.2 | 26 |
| 40 | Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2019, 20, e317-e328. | 1.1 | 26 |
| 41 | A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology, 2015, 76, 1063-1072. | 1.1 | 25 |
| 42 | Appearance of a BRAF Mutation Conferring Resistance to Crizotinib inÂNonâ€“Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion. Journal of Thoracic Oncology, 2018, 13, e66-e69. | 0.5 | 24 |
| 43 | Validity of new methods to evaluate renal function in cancer patients treated with cisplatin. Cancer Chemotherapy and Pharmacology, 2016, 77, 281-288. | 1.1 | 23 |
| 44 | Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Investigational New Drugs, 2013, 31, 1158-1168. | 1.2 | 22 |
| 45 | Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with <scp>BRAF</scp> V600 mutationâ€positive advanced cutaneous melanoma. Journal of Dermatology, 2018, 45, 397-407. | 0.6 | 22 |
| 46 | Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4. Oncotarget, 2016, 7, 33165-33178. | 0.8 | 22 |
| 47 | Successful EGFR-TKI Rechallenge of Leptomeningeal Carcinomatosis after Gefitinib-induced Interstitial Lung Disease. Japanese Journal of Clinical Oncology, 2013, 43, 422-425. | 0.6 | 20 |
| 48 | Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with <scp>ABCB</scp>1 polymorphism. Cancer Science, 2016, 107, 1117-1123. | 1.7 | 20 |
| 49 | Malignant pleural effusion as a predictor of the efficacy of antiâ€PDâ€1 antibody in patients with nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 815-822. | 0.8 | 20 |
| 50 | Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies. JTO Clinical and Research Reports, 2021, 2, 100108. | 0.6 | 20 |
| 51 | Prediction of Glomerular Filtration Rate in Cancer Patients by an Equation for Japanese Estimated Glomerular Filtration Rate. Japanese Journal of Clinical Oncology, 2013, 43, 271-277. | 0.6 | 19 |
| 52 | A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Nonâ€“Small Cell Lung Carcinoma. Journal of Thoracic Oncology, 2019, 14, 1818-1827. | 0.5 | 18 |
| 53 | Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1229-1236. | 2.0 | 18 |
| 54 | Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 66, 935-943. | 1.1 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | A phase I study of resminostat in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2015, 75, 1155-1161. | 1.1 | 17 |
| 56 | Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2Âh after a meal in patients with lung cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 125-132. | 1.1 | 17 |
| 57 | Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Nonâ€“small-cell Lung Cancer Developing After Surgery. Clinical Lung Cancer, 2017, 18, e441-e448. | 1.1 | 17 |
| 58 | Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line. Investigational New Drugs, 2013, 31, 293-303. | 1.2 | 16 |
| 59 | Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide. Clinical Journal of Gastroenterology, 2014, 7, 255-259. | 0.4 | 16 |
| 60 | Phase I, multicenter, openâ€label, doseâ€escalation study of sonidegib in Asian patients with advanced solid tumors. Cancer Science, 2016, 107, 1477-1483. | 1.7 | 16 |
| 61 | Firstâ€inâ€human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer Science, 2020, 111, 571-579. | 1.7 | 16 |
| 62 | Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101). PLoS ONE, 2015, 10, e0143072. | 1.1 | 16 |
| 63 | Impact of <scp>KRAS</scp> mutation on response and outcome of patients with stageÂ<scp>III</scp> nonâ€squamous nonâ€small cell lung cancer. Cancer Science, 2015, 106, 1402-1407. | 1.7 | 15 |
| 64 | Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors. Investigational New Drugs, 2016, 34, 66-74. | 1.2 | 15 |
| 65 | Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK -Rearranged Nonâ€“Small-Cell Lung Cancer: AÂRetrospective Analysis. Clinical Lung Cancer, 2017, 18, e251-e258. | 1.1 | 15 |
| 66 | Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. Biomarkers in Medicine, 2017, 11, 721-731. | 0.6 | 15 |
| 67 | Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression. ESMO Open, 2018, 3, e000292. | 2.0 | 15 |
| 68 | Left atrial extension of metastatic lung tumor via pulmonary vein: report on the first case of Ewing sarcoma. Rare Tumors, 2010, 2, 151-153. | 0.3 | 14 |
| 69 | Treatment and relapse of interstitial lung disease in nivolumabâ€treated patients with nonâ€“small cell lung cancer. Cancer Science, 2021, 112, 1506-1513. | 1.7 | 14 |
| 70 | Medical treatment involving investigational drugs and genetic profile of thymic carcinoma. Lung Cancer, 2016, 93, 77-81. | 0.9 | 13 |
| 71 | The first case of SMARCB1 (INI1) - deficient squamous cell carcinoma of the pleura: a case report. BMC Cancer, 2018, 18, 398. | 1.1 | 13 |
| 72 | Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phaseÂ1 study. International Journal of Urology, 2018, 25, 922-928. | 0.5 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Phase II trial of Sâ€1 treatment as palliativeâ€intent chemotherapy for previously treated advanced thymic carcinoma. Cancer Medicine, 2020, 9, 7418-7427. | 1.3 | 13 |
| 74 | Fiveâ€year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced nonâ€smallâ€cell lung cancer. Cancer Science, 2020, 111, 1933-1942. | 1.7 | 13 |
| 75 | Clinicopathological Features in Young Patients Treated for Small-Cell Lung Cancer: Significance of Immunohistological and Molecular Analyses. Clinical Lung Cancer, 2014, 15, 244-247. | 1.1 | 12 |
| 76 | Tremelimumab-associated tumor regression following after initial progression: two case reports. Immunotherapy, 2016, 8, 9-15. | 1.0 | 12 |
| 77 | Efficacy and safety of osimertinib in a Japanese compassionate use program. Japanese Journal of Clinical Oncology, 2017, 47, 625-629. | 0.6 | 12 |
| 78 | Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis. Journal of Thoracic Disease, 2019, 11, 2965-2972. | 0.6 | 11 |
| 79 | Risk factors for pneumonitis in patients with nonâ€small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis. Thoracic Cancer, 2022, 13, 724-731. | 0.8 | 10 |
| 80 | Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients. PLoS ONE, 2014, 9, e104215. | 1.1 | 9 |
| 81 | Phase II study of amrubicin at a dose of 45 mg/m<sup>2</sup>in patients with previously treated small-cell lung cancer. Japanese Journal of Clinical Oncology, 2015, 45, 941-946. | 0.6 | 9 |
| 82 | Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization. Journal of Clinical Oncology, 2015, 33, 2051-2061. | 0.8 | 9 |
| 83 | Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 641-651. | 1.2 | 8 |
| 84 | Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity. International Journal of Radiation Oncology Biology Physics, 2016, 94, 155-162. | 0.4 | 8 |
| 85 | Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study. Investigational New Drugs, 2018, 36, 259-268. | 1.2 | 8 |
| 86 | Long-term survival without surgery in NSCLC patients with synchronous brain oligometastasis: systemic chemotherapy revisited. Journal of Thoracic Disease, 2018, 10, 1696-1702. | 0.6 | 8 |
| 87 | Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption. Journal of Dermatology, 2019, 46, 18-25. | 0.6 | 8 |
| 88 | Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for nonâ€“small cell lung cancer. Cancer Science, 2021, 112, 1495-1505. | 1.7 | 8 |
| 89 | A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 991-998. | 1.1 | 6 |
| 90 | Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines. Oncology Reports, 2013, 30, 1802-1806. | 1.2 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 234-240.e2. | 1.1 | 6 |
| 92 | Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations. ESMO Open, 2018, 3, e000399. | 2.0 | 6 |
| 93 | Pharmacokinetic study of the oral fluorouracil antitumor agent Sâ€1 in patients with impaired renal function. Cancer Science, 2019, 110, 1987-1994. | 1.7 | 6 |
| 94 | Mixed response to osimertinib and the beneficial effects of additional local therapy. Thoracic Cancer, 2019, 10, 738-743. | 0.8 | 6 |
| 95 | Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing. Lung Cancer, 2019, 128, 20-25. | 0.9 | 6 |
| 96 | Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies. Cancer Chemotherapy and Pharmacology, 2021, 87, 53-64. | 1.1 | 6 |
| 97 | Firstâ€inâ€human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. Cancer Science, 2021, 112, 1514-1523. | 1.7 | 6 |
| 98 | Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials. ESMO Open, 2020, 5, e000653. | 2.0 | 5 |
| 99 | Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. Cancer Medicine, 2021, 10, 2350-2358. | 1.3 | 5 |
| 100 | Effect of sequential chemoradiotherapy in patients with limited-disease small-cell lung cancer who were ineligible for concurrent therapy: a retrospective study at two institutions. Japanese Journal of Clinical Oncology, 2018, 48, 82-88. | 0.6 | 4 |
| 101 | Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991â€“2015. Investigational New Drugs, 2019, 37, 166-174. | 1.2 | 4 |
| 102 | Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 3039-3039. | 0.8 | 4 |
| 103 | Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer. Cancer Science, 2019, 110, 3573-3583. | 1.7 | 3 |
| 104 | Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 1783-1791. | 3.2 | 3 |
| 105 | Serum Total Bilirubin as a Predictive Factor for Severe Neutropenia in Lung Cancer Patients Treated with Cisplatin and Irinotecan. Japanese Journal of Clinical Oncology, 2007, 37, 358-364. | 0.6 | 2 |
| 106 | Regulation of MET Kinase Inhibitor Resistance by Copy Number of <I>MET</I> in Gastric Carcinoma Cells. Oncology Research, 2014, 21, 287-293. | 0.6 | 2 |
| 107 | Secondary Osteosarcoma Developing 10 Years after Chemoradiotherapy for Non-small-cell Lung Cancer. Japanese Journal of Clinical Oncology, 2014, 44, 191-194. | 0.6 | 2 |
| 108 | Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience. Investigational New Drugs, 2017, 35, 392-396. | 1.2 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Next-Generation Sequencer Analysis of Pulmonary Pleomorphic Carcinoma With a CD74-ROS1 Fusion Successfully Treated With Crizotinib. Journal of Thoracic Oncology, 2019, 14, e106-e108. | 0.5 | 2 |
| 110 | Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma. Oncologist, 2022, 27, e703-e722. | 1.9 | 2 |
| 111 | Successful neutrophil engraftment by reduced use of granulocyte colony-stimulating factor after allogeneic hematopoietic stem cell transplantation with mycophenolate mofetil for graft-versus-host disease prophylaxis. International Journal of Hematology, 2011, 93, 765-770. | 0.7 | 1 |
| 112 | Improved survival among patients enrolled in oncology phase 1 trials in recent decades. Cancer Chemotherapy and Pharmacology, 2020, 85, 449-459. | 1.1 | 1 |
| 113 | Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).. Journal of Clinical Oncology, 2014, 32, 347-347. | 0.8 | 1 |
| 114 | Adjuvant Chemotherapy in Patients with Completely Resected Small Cell Lung Cancer: A Retrospective Analysis of 26 Consecutive Cases. Japanese Journal of Clinical Oncology, 2014, 44, 835-840. | 0.6 | 0 |
| 115 | Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan. International Journal of Clinical Oncology, 2017, 22, 780-785. | 1.0 | 0 |
| 116 | Efficacy of surgery for skin cancers initially suspected to be carcinoma of unknown primary: a retrospective observational study. International Journal of Dermatology, 2021, , . | 0.5 | 0 |
| 117 | Programmed cell death 1 (PD-1) and its ligand (PD-L1) expression in thymic epithelial tumors (TETs): Impact on the treatment efficacy and alteration in expression after chemotherapy (C).. Journal of Clinical Oncology, 2015, 33, 7515-7515. | 0.8 | 0 |
| 118 | Possible utility of actinin-4 as a predictive biomarker of the efficacy of postoperative adjuvant chemotherapy for completely resected early stage lung adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, e20003-e20003. | 0.8 | 0 |
| 119 | Successful <scp>IMRT</scp> and concurrent chemotherapy for a patient with intrathoracic extensiveâ€stage small cell lung cancer. Respirology Case Reports, 2022, 10, e0919. | 0.3 | 0 |